FOxTROT: Randomized phase II study of neoadjuvant chemotherapy with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer by Gray, R, Morton, D, Brown, G, Ferry, DR, Magill, L, Quirke, P, Seymour, M, Warren, B, Grp, F

FOxTROT: Randomized phase II study of neoadjuvant chemotherapy (CT) with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer: Planned interim report by Morton, D, Magill, L, Handley, K, Brown, G, Ferry, DR, Gray, Z, Quirke, P, Seymour, M, Warren, B, Gray, R, Grp, F

Accuracy of radiological staging in identifying high-risk colon cancer patients suitable for neoadjuvant chemotherapy: a multicentre experience. by Dighe, S, Swift, I, Magill, L, Handley, K, Gray, R, Quirke, P, Morton, D, Seymour, M, Warren, B, Brown, G

“… AIM: A pilot study was undertaken to determine the accuracy of computed tomography (CT) staging in identifying patients with high-risk colon cancers who would be considered as candidates for a neoadjuvant therapy trial (FOxTROT) and those at low risk (T1/T2) who would be excluded. …”

Ontological user profiling in recommender systems. by Middleton, SE, Shadbolt, N, Roure, D

“…Our two experimental systems, Quickstep and Foxtrot, create user profiles from unobtrusively monitored behaviour and relevance feedback, representing the profiles in terms of a research paper topic ontology. …”

In-depth clinical and biological exploration of DNA damage immune response as a biomarker for oxaliplatin use in colorectal cancer by Malla, SB, Fisher, DJ, Domingo, E, Blake, A, Hassanieh, S, Redmond, KL, Richman, SD, Youdell, M, Walker, SM, Logan, GE, Chatzipli, A, Amirkhah, R, Humphries, MP, Craig, SG, McDermott, U, Seymour, MT, Morton, DG, Quirke, P, West, NP, Salto-Tellez, M, Kennedy, RD, Johnston, PG, Tomlinson, I, Koelzer, VH, Campo, L, Kaplan, RS, Longley, DB, Lawler, M, Maughan, TS, Brown, LC, Dunne, PD

“…</p> <p><strong>Experimental Design:</strong> Samples and clinical data were assessed according to DDIR status from patients who received either 5-fluorouracil (5-FU) or 5FUFA (bolus and infusion 5-FU with folinic acid) plus oxaliplatin (FOLFOX) within the FOCUS trial (n = 361, stage IV), or neoadjuvant FOLFOX in the FOxTROT trial (n = 97, stage II/III). Whole transcriptome, mutation, and IHC data of these samples were used to interrogate the biology of DDIR in colorectal cancer.…”